Discounted Cash Flow (DCF) Analysis Levered
Edesa Biotech, Inc. (EDSA)
$0.8859
+0.03 (+3.82%)
All numbers are in Millions, Currency in USD
Free Cash Flow
Year A/P | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Projected | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
| Revenue | 0.21 | 0.41 | 0.33 | 0.45 | 0.62 | 0.85 | 1.16 | 1.59 | 2.17 | 2.98 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (%) | ||||||||||
| Operating Cash Flow | -4.62 | -4.85 | -4.99 | -13.66 | -12.28 | -16.73 | -22.92 | -31.40 | -43.01 | -58.92 |
| Operating Cash Flow (%) | ||||||||||
| Capital Expenditure | -0.38 | -0.01 | -0.03 | -0.01 | -5.66 | -1.88 | -2.57 | -3.52 | -4.83 | -6.61 |
| Capital Expenditure (%) | ||||||||||
| Free Cash Flow | -5 | -4.85 | -5.02 | -13.67 | -17.94 | -18.61 | -25.49 | -34.92 | -47.84 | -65.53 |
Weighted Average Cost Of Capital
| Share price | $ 0.8,859 |
|---|---|
| Beta | 0.797 |
| Diluted Shares Outstanding | 12.08 |
| Cost of Debt | |
| Tax Rate | -0.00 |
| After-tax Cost of Debt | 5.00% |
| Risk-Free Rate | |
| Market Risk Premium | |
| Cost of Equity | 7.544 |
| Total Debt | 0.02 |
| Total Equity | 10.70 |
| Total Capital | 10.72 |
| Debt Weighting | 0.18 |
| Equity Weighting | 99.82 |
| Wacc |
Build Up Free Cash Flow
Year A/P | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Projected | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
| Revenue | 0.21 | 0.41 | 0.33 | 0.45 | 0.62 | 0.85 | 1.16 | 1.59 | 2.17 | 2.98 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -4.62 | -4.85 | -4.99 | -13.66 | -12.28 | -16.73 | -22.92 | -31.40 | -43.01 | -58.92 |
| Capital Expenditure | -0.38 | -0.01 | -0.03 | -0.01 | -5.66 | -1.88 | -2.57 | -3.52 | -4.83 | -6.61 |
| Free Cash Flow | -5 | -4.85 | -5.02 | -13.67 | -17.94 | -18.61 | -25.49 | -34.92 | -47.84 | -65.53 |
| WACC | ||||||||||
| PV LFCF | -10.22 | -12.47 | -12.03 | -15.33 | -19.52 | -24.87 | -31.68 | |||
| SUM PV LFCF | -148.76 |
Terminal Value
| Growth in perpetuity method: | |
|---|---|
| Long-term growth rate | |
| WACC (%) | 7.54 |
| Free cash flow (t + 1) | -66.84 |
| Terminal Value | -1,206.56 |
| Present Value of Terminal Value | -838.88 |
Intrinsic Value
| Enterprise Value | -987.64 |
|---|---|
| Net Debt | -7.07 |
| Equity Value | -980.57 |
| Shares Outstanding | 12.08 |
| Equity Value Per Share | -81.19 |